| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HTATIP2 |
| Uniprot No | Q9BUP3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-242aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAETEALSKLREDFRMQNKSVFILGASGET GRVLLKEILEQGLFSKVTLIGRRKLTFDEEAYKNVNQEVVDFEKLDDYAS AFQGHDVGFCCLGTTRGKAGAEGFVRVDRDYVLKSAELAKAGGCKHFNLL SSKGADKSSNFLYLQVKGEVEAKVEELKFDRYSVFRPGVLLCDRQESRPG EWLVRKFFGSLPDSWARGHSVPVVTVVRAMLNNVVRPRDKQMELLENKAI HDLGKAHGSLKP |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HTATIP2(TIP30/CC3)重组蛋白的模拟参考文献及摘要概括：
---
1. **文献名称**: *"TIP30. a novel protein that interacts with HIV-1 Tat protein and regulates Tat-activated transcription"*
**作者**: Xiao, H., et al.
**摘要**: 该研究首次克隆并鉴定了HTATIP2(TIP30)，发现其作为HIV Tat相互作用蛋白，通过调控转录活性参与细胞凋亡。实验表明TIP30过表达可诱导肿瘤细胞凋亡，提示其抑癌功能。
2. **文献名称**: *"Role of TIP30 in the suppression of metastatic melanoma progression"*
**作者**: Shtivelman, E., et al.
**摘要**: 研究发现HTATIP2通过抑制基质金属蛋白酶(MMPs)的表达，阻碍肿瘤细胞侵袭和转移。动物模型中，重组TIP30蛋白显著降低黑色素瘤肺转移，表明其潜在治疗价值。
3. **文献名称**: *"Recombinant TIP30 protein inhibits angiogenesis by targeting endothelial cell migration"*
**作者**: Zhang, Y., et al.
**摘要**: 研究利用原核系统表达纯化重组HTATIP2蛋白，证实其通过阻断VEGF信号通路抑制内皮细胞迁移及血管生成，为抗肿瘤药物开发提供实验依据。
4. **文献名称**: *"TIP30 regulates autophagy-dependent cell death in hepatocellular carcinoma"*
**作者**: Liu, W., et al.
**摘要**: 该文揭示重组HTATIP2通过激活自噬途径诱导肝癌细胞死亡，分子机制涉及与mTOR通路的相互作用，为靶向自噬的癌症治疗策略提供新思路。
---
注：以上内容为模拟生成，实际文献需通过学术数据库检索确认。
HTATIP2 (HIV-1 Tat-interacting protein 2), also known as TIP30 or CC3. is a tumor suppressor gene encoding a 30 kDa protein initially identified through its interaction with the HIV-1 Tat protein. This multifunctional protein plays critical roles in apoptosis, angiogenesis inhibition, and metastasis suppression. Structurally, HTATIP2 contains a short-chain dehydrogenase/reductase (SDR) domain and functions as a cofactor-dependent transcription regulator, influencing pathways like NF-κB and STAT3 signaling.
In cancer biology, HTATIP2 is frequently downregulated in various malignancies including hepatocellular carcinoma, breast cancer, and non-small cell lung cancer. Its loss correlates with poor prognosis, enhanced tumor growth, and increased vascularization. Mechanistically, HTATIP2 induces apoptosis through caspase activation while inhibiting angiogenesis by suppressing pro-angiogenic factors like VEGF.
Recombinant HTATIP2 protein, typically produced in E. coli or mammalian expression systems, retains these biological activities. The production process involves cloning the coding sequence into expression vectors, followed by affinity chromatography purification using tags like His-tag. Quality control includes SDS-PAGE, Western blotting, and functional assays to verify apoptosis-inducing and angiogenesis-inhibiting capabilities.
This recombinant protein serves as a vital tool for studying tumor suppression mechanisms, screening anticancer compounds, and developing gene therapies. Current research explores its potential in combination therapies and as a biomarker for cancer progression. The conserved structure across species (human, mouse, rat) facilitates cross-species experimental models, while ongoing studies investigate its epigenetic regulation and interaction networks in tumor microenvironments.
×
